Genentech Archives -

Roche adds to pipeline with Poseida, Kiniksa deals

Phil Taylor CAR-T therapies, Genentech, Kiniksa Pharmaceuticals, partnering, Poseida Therapeutics, prurigo nodularis, Roche 0 Comment

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline

Roche adds to pipeline with Poseida, Kiniksa deals

https://pharmaphorum.com/news/roche-adds-to-pipeline-with-poseida-kiniksa-deals/

News/ News/ News/ Oncology/ R&D

Roche rings Bicycle bell again, grabbing another cancer target

Phil Taylor Bicycle Therapeutics, Genentech, immuno-oncology, Oncology, partnering, Roche 0 Comment

Roche’s Genentech unit has gone all in on its collaboration with UK biotech Bicycle Therapeutics, taking up an

Roche rings Bicycle bell again, grabbing another cancer target

https://pharmaphorum.com/news/roche-rings-bicycle-bell-again-grabbing-another-cancer-target/

News/ News/ R&D

Another amyloid miss in Alzheimer’s as Roche’s crenezumab fails trial

Phil Taylor AC Immune, Alzheimer's disease, amyloid, crenezumab, gantenerumab, Genentech, Roche 0 Comment

The litany of failed trials of amyloid-targeting drugs for Alzheimer’s disease has added another verse, as Roche concedes

Another amyloid miss in Alzheimer’s as Roche’s crenezumab fails trial

https://pharmaphorum.com/news/another-amyloid-miss-in-alzheimers-as-roches-crenezumab-fails-trial/

News/ News/ R&D

Scenic Bio raises $31m for genetic modifier platform

Phil Taylor financing, Genentech, genetic modifier, Roche, Scenic Biotech 0 Comment

18 months after signing its first partnering deal with Genentech, Scenic Biotech has raised $31 million in first-round

Scenic Bio raises $31m for genetic modifier platform

https://pharmaphorum.com/news/scenic-bio-raises-31m-for-genetic-modifier-platform/

News/ News/ Oncology

Roche dives further into cancer cell therapy with Adaptimmune deal

Phil Taylor Adaptimmune, cell therapy, Genentech, immuno-oncology, Oncology, partnering, Roche 0 Comment

Roche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for

Roche dives further into cancer cell therapy with Adaptimmune deal

https://pharmaphorum.com/news/roche-dives-further-into-cancer-cell-therapy-with-adaptimmune-deal/

News/ News/ R&D

AC Immune claims half a win for tau drug in Alzheimer’s trial

Phil Taylor AC Immune, Alzheimer's disease, antibody, Genentech, neurology, Roche, Tau 0 Comment

Shares in AC Immune leaped today after the company said its tau-targeting Alzheimer’s disease candidate semorinemab hit one

AC Immune claims half a win for tau drug in Alzheimer’s trial

https://pharmaphorum.com/news/ac-immune-claims-half-a-win-for-tau-drug-in-alzheimers-trial/

Market Access/ News/ News

Amid Actemra shortage, WHO asks Roche to ensure equitable access

Phil Taylor Actemra, coronavirus, COVID-19, drug shortages, Genentech, Roche 0 Comment

Roche’s arthritis drug Actemra has become a key treatment for people with severe COVID-19, leading to shortages, and

Amid Actemra shortage, WHO asks Roche to ensure equitable access

https://pharmaphorum.com/news/amid-actemra-shortage-who-asks-roche-to-ensure-equitable-access/

News/ News/ R&D

RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-ups

Richard Staines Atalanta Therapeutics, Biogen, Genentech, Huntington's, neurology, Parkinson's, Roche 0 Comment

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who

RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-ups

https://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/

News/ News/ R&D/ Top stories

AC Immune poleaxed on Alzheimer’s study fail

Phil Taylor AC Immune, Alzheimer's disease, Genentech, Roche, Tau 0 Comment

Shares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a

AC Immune poleaxed on Alzheimer’s study fail

https://pharmaphorum.com/news/ac-immune-poleaxed-on-alzheimers-study-fail/

Trending

Genentech

Login